|
Scritto da BMC Nephrology
|
 Background:Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim ofthis study is to investigate whether specific treatment reverts ACL-associated renaldysfunction.Methods:A prospective study was conducted with 37 patients with ACL. Urinary concentrating andacidification ability was assessed before and after treatment with pentavalent antimonial.Results:The patients mean age was 35.612 years and 19 were male. Before treatment, urinaryconcentrating defect (U/Posm <2.8) was identified in 27 patients (77 %) and urinaryacidification defect in 17 patients (46 %). No significant glomerular dysfunction wasobserved before and after specific ACL treatment. There was no reversion of urinaryconcentrating defects, being observed in 77 % of the patients before and in 88 % aftertreatment (p = 0.344). Urinary acidification defect was corrected in 9 patients after treatment,reducing its prevalence from 40 % before to only 16 % after treament, (p = 0.012).Microalbuminuria higher than 30 mg/g was found in 35 % of patients before treatment and inonly 8 % after treatment. Regarding fractional excretion of sodium, potassium, calcium,phosphorus and magnesium, there was no significant difference between pre and posttreatmentperiod.Conclusion:As previously described, urinary concentrating and acidification defects were found in animportant number of patients with ACL. Present results demonstrate that only some patientsrecover urinary acidification capacity, while no one returned to normal urinary concentrationcapacity.
Fonte: BMC Nephrology |
